Weekly Wellness Spotlight

For this week’s wellness spotlight, we highlight another great article Dr. Susan Summerton posted to our OWNS facebook site.

Behaviour change, weight loss and remission of Type 2 diabetes: a community-based prospective cohort study
H. Dambha-Miller A. J. Day J. Strelitz G. Irving S. J. Griffin
First published: 03 September 2019 https://doi.org/10.1111/dme.14122

Dieting doesn’t have to be drastic to reverse Type 2 diabetes.


In a population-based sample of adults with screen-detected Type 2 diabetes, weight loss of
≥10% early in the disease trajectory was associated with a doubling of the likelihood of remission at 5 years. This was achieved without intensive lifestyle interventions or extreme calorie restrictions. Greater attention should be paid to enabling people to achieve weight loss following diagnosis of Type 2 diabetes.

What’s new?

Biochemical remission of Type 2 diabetes in the absence of pharmacological or surgical intervention has been shown to be achievable.
This has been previously demonstrated in short-term studies and only in selected populations
through intensive weight loss programmes.
We found that weight loss of ≥10% in the first few years after diagnosis was strongly associated with remission of Type 2 diabetes at 5 years.
This was achieved without intensive lifestyle interventions or extreme calorie restrictions.
Our findings should inform discussions with people who have newly diagnosed Type 2 diabetes as a motivation towards remission of the disease without restrictive and sometimes unachievable calorie restrictions.




Oral Omega-3 Supplementation Lowers Intraocular Pressure in Normotensive Adults
Laura Elizabeth Downie; Algis Jonas Vingrys

Purpose: Elevated intraocular pressure (IOP) is the major modifiable risk factor for the
sight-threatening eye disease, glaucoma. We investigated whether oral omega-3 supplements affect IOP in normotensive adults.

Methods: We undertook a pooled analysis of data from two double-masked, placebo-controlled randomized trials (Australian New Zealand Clinical Trials Registry, ACTRN12614001019695, ACTRN12615000173594) that investigated the efficacy and safety of oral omega-3 supplementation for treating ocular surface inflammation. Recruitment involved adults (n = 105) with IOP <21 mm Hg, and without a current or prior glaucoma diagnosis. Participants were randomly allocated to either an oral omega-3 (∼1000 mg/day eicosapentaenoic acid + ∼500 mg/day docosahexaenoic acid ± 900 mg/day α-linolenic acid) or placebo (olive oil, 1500 mg/day) supplement. IOP was quantified at baseline and after 3 months of supplementation (day 90). Change in IOP, relative to baseline, was compared between groups.

Results: At baseline, participants were of similar age (omega-3/placebo groups: mean ± SEM, 33.7 ± 1.7, n = 72/35.6 ± 3.0 years, n = 33), sex (65%/79% female), and had similar IOP (14.3 ± 0.3/13.8 ± 0.5 mm Hg). At day 90, IOP was reduced to 13.6 ± 0.3 mm Hg in the omega-3 group; controls had a slight IOP increase to 14.2 ± 0.4 mm Hg (P < 0.05).

Conclusions: Oral omega-3 supplementation for 3 months significantly reduced IOP in normotensive adults. To our knowledge, this is the first study to report that omega-3 fatty acids lower IOP in humans.

Translational Relevance: These findings justify further investigation into the therapeutic potential of omega-3 supplementation for reducing IOP, to prevent and/or treat conditions with IOP elevation, including ocular hypertension and glaucoma.